https://www.selleckchem.com/products/bi-3231.html
5% [185/366], P=.108; monthly 53.7% [196/365], P=.012; vs placebo 44.5% [159/357]) or the monthly headache day count at Months 1, 2, and 3 criteria for reversion (quarterly 31.2% [114/366], P=.008; monthly 33.7% [123/365], P=.001; vs placebo 22.4% [80/357]). Patients with CM who reported previous topiramate or onabotulinumtoxinA use, concomitant preventive medication use, or medication overuse were less likely to revert to EM. Fremanezumab may offer the benefit of reversion from CM to EM, based on a reduction in the number of headache d
Like
Comment
Share
